home / stock / mtem / mtem news

MTEM News and Press, Molecular Templates Inc. From 03/01/23

Stock Information
Company Name: Molecular Templates Inc.
Stock Symbol: MTEM
Market: NASDAQ
Website: mtem.com
Menu
MTEM MTEM Quote MTEM Short MTEM News MTEM Articles MTEM Message Board
Get MTEM Alerts

News, Short Squeeze, Breakout and More Instantly...
MTEM - Molecular Templates Announces Participation in Upcoming Conferences

AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, enginee...
MTEM - Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineer...

MTEM - Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, en...

MTEM - Molecular Templates GAAP EPS of -$0.44 beats by $0.04, revenue of $4.24M beats by $1.16M

Molecular Templates press release ( NASDAQ: MTEM ): Q3 GAAP EPS of -$0.44 beats by $0.04 . Revenue of $4.24M (+78.2% Y/Y) beats by $1.16M . For further details see: Molecular Templates GAAP EPS of -$0.44 beats by $0.04, revenue of $4.24M beats by $1.16M ...
MTEM - Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results

AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, en...

MTEM - Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, en...

MTEM - Molecular Templates Announces Participation in Four Upcoming Conferences

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineer...
MTEM - Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Molecular Templates press release ( NASDAQ: MTEM ): Q2 GAAP EPS of -$0.44 misses by $0.01 . Revenue of $4.42M (-70.8% Y/Y) misses by $2.6M . As of June 30, 2022, MTEM’s cash and investments totaled $104.4M. MTEM’s current cash and investments are ...

MTEM - Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results

AUSTIN, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, en...

MTEM - Molecular Templates' Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs

AUSTIN, Texas, June 06, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineer...
Previous 10 Next 10